Results 61 to 70 of about 527 (122)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Ahmad Masri, Iacopo Olivotto
doaj   +1 more source

Efficacy and safety of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4 [PDF]

Background This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy (nHCM). Methods Patients with symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤
Sohn, Regina L., Sohn, Regina L, Nagueh, Sherif F, Malik, Fady I, Owens, Anjali T, Watkins, Hugh, Jacoby, Daniel L., Malik, Fady I., Solomon, Scott D., Nagueh, Sherif F., Heitner, Stephen B., Wohltman, Amy, Solomon, Scott D, Heitner, Stephen B, Jacoby, Daniel L, Tower-Rader, Albree, Coats, Caroline J., Kramer, Christopher M., Garcia-Pavia, Pablo, Wong, Timothy C, Masri, Ahmad, Abraham, Theodore P, Fifer, Michael A, Meng, Lisa, Saberi, Sara, Abraham, Theodore P., Sherrid, Mark V., Rader, Florian, Sherrid, Mark V, Kupfer, Stuart, Maron, Martin S., Barriales-Villa, Roberto, Maron, Martin S, Owens, Anjali T., Kramer, Christopher M, Wong, Timothy C., REDWOOD-HCM Investigators, Coats, Caroline J, Fifer, Michael A., Choudhury, Lubna, Olivotto, Iacopo   +40 more
core   +1 more source

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond

The Egyptian Heart Journal
Background A cardiac condition marked by excessive growth of heart muscle cells, hypertrophic cardiomyopathy (HCM) is a complex genetic disorder characterized by left ventricular hypertrophy, microvascular ischemia, myocardial fibrosis, and diastolic ...
Khadija Sarwer, Saeeda Lashari, Nida Rafaqat, Maher, Abdul Raheem, Muneeb Ur Rehman, Syed Muhammad Iraj Abbas   +6 more
doaj   +1 more source

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

Open Heart
Background Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman, Arfa Akram, Bisma Akram, Momina Maham, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Furqan Yaqub   +7 more
doaj   +1 more source

Hypertrophic Cardiomyopathy in the Era of Targeted Therapy: The Role of Cardiac Myosin Inhibitors, Contemporary Sudden Cardiac Death Risk Stratification, and the Importance of Differential Diagnosis — A Narrative Review

Journal of Education, Health and Sport
Introduction and purpose: Hypertrophic cardiomyopathy (HCM) is a common genetic myocardial disease characterized by unexplained left ventricular hypertrophy, phenotypic heterogeneity, and a clinical course ranging from asymptomatic presentation to heart
Julia Parda, Jakub Bundyra, Dominika Janik, Oliwia Zuzanna Gańska, Agata Sochocka, Zuzanna Zapart, Martyna Szepietowska, Nina Nowicka, Alicja Sikorska, Emil Mian   +9 more
doaj   +1 more source

Issue Information

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 1893-1896, December 2025.
wiley   +1 more source

Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities

Biomedicines
Hypertrophic cardiomyopathy (HCM) is often associated with left ventricular outflow tract (LVOT) obstruction, which affects a substantial proportion of patients.
Marco Maria Dicorato, Gaetano Citarelli, Francesco Mangini, Rossella Alemanni, Miriam Albanese, Sebastiano Cicco, Cosimo Angelo Greco, Cinzia Forleo, Paolo Basile, Maria Cristina Carella, Marco Matteo Ciccone, Andrea Igoren Guaricci, Ilaria Dentamaro   +12 more
doaj   +1 more source

Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy

Background/Aims: Obstructive HCM (oHCM) affects people across all geographic regions, ethnicities, and socioeconomic groups. In the SEQUOIA-HCM trial (NCT05186818), aficamten, an oral selective cardiac myosin inhibitor, improved exercise capacity ...
Hagège, Albert A., Masri, Ahmad, Cardim, Nuno, Kulac, Ian J., Abraham, Theodore, Tfelt-Hansen, Jacob, Düngen, Hans-Dirk, Maron, Martin S., Kupfer, Stuart, Arad, Michael, Michels, Michelle, Oreziak, Artur, Jacoby, Daniel L., Solomon, Scott D., Claggett, Brian L., Heitner, Stephen B., SEQUOIA-HCM Investigators, Ma, Chang-Sheng, Barriales‑Villa, Roberto, Coats, Caroline J., Merkely, Bela, Garcia-Pavia, Pablo, Olivotto, Iacopo   +22 more
core   +1 more source

Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies

The Egyptian Heart Journal
Background Hypertrophic cardiomyopathy (HCM) is a frequently encountered cardiac condition worldwide, often inherited, and characterized by intricate phenotypic and genetic manifestations.
Samuel Oluwadare Olalekan, Olalekan Olanrewaju Bakare, Patrick Godwin Okwute, Ifabunmi Oduyemi Osonuga, Muinat Moronke Adeyanju, Victoria Biola Edema   +5 more
doaj   +1 more source

Novel process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl) -2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide [PDF]

: The present invention relates to a novel process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, which is referred to as Aficamten and represented by the following structural
, Anonymous
core